B.Riley/FBR Downgrades Adamis Pharmaceuticals (ADMP) to Sell

B.Riley/FBR analyst Andrew D\'Silva downgraded Adamis Pharmaceuticals (NASDAQ: ADMP) from Neutral to Sell with a price target of $1.10 (from $1.90).

For an analyst ratings summary and ratings history on Adamis Pharmaceuticals click here. For more ratings news on Adamis Pharmaceuticals click here.

Shares of Adamis Pharmaceuticals closed at $1.46 yesterday.

You May Also Be Interested In

• Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
• Honasa Consumer Ltd (HONASA:IN) PT Raised to INR720 at ICICI Securities
• Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform